SymBio Pharmaceuticals

13 articles about SymBio Pharmaceuticals

• Eagle Pharmaceuticals’ Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute (“RTD”) Formulation, with Launch Expected in January 2021

  9/23/2020

  Eagle Pharmaceuticals, Inc. announced that its marketing partner, SymBio Pharmaceuticals Limited, has received regulatory approval for TREAKISYM ready-to-dilute liquid formulation from the Pharmaceuticals and Medical Devices Agency in Japan.

• Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation

  3/30/2020

  Eagle Pharmaceuticals, Inc. announced that its marketing partner SymBio Pharmaceuticals Limited has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion, a liquid bendamustine injection with a 10-minute administration time, in Japan.

• Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation

  10/7/2019

  Eagle Pharmaceuticals, Inc. announced that its marketing partner SymBio Pharmaceuticals Limited has submitted a New Drug Application for TREAKISYM ready-to-dilute liquid formulation in Japan.

• SymBio Pharmaceuticals: Initiation of Phase I Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors

  1/22/2018

  SymBio Pharmaceuticals announced today that it has initiated a Phase 1 study in Japan for oral TREAKISYM in patients with progressive solid tumors.

• Eagle Pharma Licenses Japanese Rights For Bendamustine Hydrochloride Ready-To-Dilute And Rapid Infusion Injection Products To SymBio Pharma

  9/20/2017

• SymBio Pharma Release: Initiation Of Phase III Clinical Trial On The Patient-Controlled Pain Management Drug "SyB P-1501"

  6/13/2016

• The Medicines Company And SymBio Pharmaceuticals Establish Strategic Partnership For IONSYS (Fentanyl Iontophoretic Transdermal System) In Japan

  10/7/2015

• SymBio Pharmaceuticals Announces Completion of Patient Enrollment of TREAKISYM(R) (SyB L-0501) Phase II Trial in Frontline Low-Grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

  3/6/2013

• SymBio Pharmaceuticals Announces Results Presented at American Society of Clinical Oncology 2012 Evaluating Clinical Benefits of TREAKISYM(R) (Bendamustine) in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (

  6/5/2012

• Onconova Therapeutics Inc. and SymBio Pharmaceuticals Complete License Agreement for Rigosertib, a Phase III Stage Multi-Kinase Inhibitor for Cancer

  7/8/2011

• SymBio Pharmaceuticals Raises $24M in Series E

  2/28/2011

• SymBio Pharmaceuticals and Eisai Company, Ltd. to Launch Symbenda(R) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphatic Leukemia

  9/7/2010

• Abeille Pharmaceuticals, Inc. Licenses AB-1001 to SymBio Pharmaceuticals for Commercialization in Japan and Pacific Rim Countries

  3/15/2007